Proprietary delivery edge MiDROPS proprietary technology enables stable, safe formulations that deliver substantial drug amounts into the eye for topical instillation, creating opportunities to partner on ocular drug delivery programs for lipophilic compounds and to leverage formulation IP in preclinical studies.

Diverse disease models EyeCRO offers extensive ophthalmic preclinical models including dry eye, AMD, diabetic retinopathy, glaucoma, and inflammatory or vascular conditions, backed by decades of combined expertise to accelerate pharmacology, efficacy, PK/tox and formulation development.

Collaboration pedigree A track record with MPI Research to develop large mammalian ocular models and active engagement with the ARVO community signal readiness for co-development, consortia, and long-term CRO partnerships.

Strategic fit EyeCRO’s specialization and size position it as a high-value partner for midsize pharma and biotech firms pursuing specialized ocular programs, offering end-to-end preclinical services from pharmacology to formulation and analytics.

Growth signals Recent leadership hiring in pharmacology and bioanalytics and ongoing conference participation indicate capability expansion and a path toward broader, higher-value client engagements.